The natural history of chronic hepatitis B
Chronic hepatitis B
and C cause thousands of cases of liver cancer, liver disease, and death each year--taking the heaviest toll among Asians, Pacific Islanders, and blacks in the United States.
Chronic hepatitis B
infection is a potentially life-threatening disease and is a serious global public health issue.
The work, which Aach calls "the most promising approach to date," does not prove absolutely that the combination treatment can cure chronic hepatitis B
, both Aach and the researchers point out, because of the short follow-up period.
Under the terms of the agreement, Pharmasset gained development and commercialization rights to Clevudine, and Bukwang received an option to Racivir for the treatment of chronic Hepatitis B
PEGASYS is well-known to physicians as a highly effective treatment for chronic hepatitis C and we are glad the EU Commission has recognised the benefits it also offers to patients with chronic hepatitis B
," said William M.
This year's program will feature educational events in four cities where prevalence of chronic hepatitis B
is high -- San Francisco, Los Angeles, Honolulu and New York.
We set out to explore the potential of PEGASYS in treating chronic hepatitis B
and demonstrated its effectiveness against both forms of the virus and against the two leading medications used to treat it today, lamivudine and conventional interferon," he said.
The indication for Hepsera recommended by the CPMP is for the treatment of chronic hepatitis B
in adults with compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis; or decompensated liver disease.
The American Liver Foundation wants to highlight these positive results, but remind people that chronic hepatitis B
and C are very serious diseases that affect over five million Americans and that the prevalence of chronic hepatitis C infection is actually increasing.
The application is supported by data from Phase III studies in hepatitis B "e" antigen-positive patients, hepatitis B "e" antigen-negative patients and chronic hepatitis B
patients with lamivudine-resistant HBV.
TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B
& C and embolotherapy treatments for tumors, today announced that it has entered into a research collaboration with Defence Research and Development Canada - Suffield (DRDC Suffield) to carry out research on applying ViRexx's proprietary Chimigen(TM) vaccine platform for biodefense.
May 15 /PRNewswire/ -- Today, the Hepatitis B Foundation and Bristol-Myers Squibb Company announced the launch of the third-annual "AIM for the B: Awareness, Involvement and Mobilization for Chronic Hepatitis B
" program, a public education initiative designed to elevate awareness of chronic hepatitis B
as a serious health issue in the United States and emphasize the importance of disease management, especially among Asian Americans who are disproportionately affected with the disease.
The study will primarily evaluate the safety and tolerability of the HBV immunotherapeutic, pdpSC18, administered by PMED(TM), PowderMed's needle-free delivery technology, in patients with chronic Hepatitis B
infection, both in combination with lamivudine and as monotherapy.
May 9 /PRNewswire/ -- In recognition of the need to increase education and awareness for chronic hepatitis B
, the Hepatitis B Foundation and Bristol-Myers Squibb Company are partnering to host "AIM for the B: Awareness, Involvement and Mobilization for Chronic Hepatitis B
," a public education program designed to elevate the urgency for prioritizing chronic hepatitis B
as a serious health issue in the United States.